This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Genentech/Roche
Information provided by (Responsible Party):
Southwest Oncology Group
ClinicalTrials.gov Identifier:
NCT02164916
First received: June 13, 2014
Last updated: February 23, 2017
Last verified: February 2017
  Purpose
This randomized phase II trial studies how well irinotecan hydrochloride and cetuximab with or without vemurafenib works in treating patients with colorectal cancer that has spread to nearby tissue or lymph nodes, that has spread to other places in the body, or cannot be removed by surgery. Irinotecan hydrochloride and vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, may block the ability of tumor cells to grow and spread. It is not yet known whether irinotecan hydrochloride and cetuximab are more effective with or without vemurafenib in treating colorectal cancer.

Condition Intervention Phase
Colorectal Cancer Biological: cetuximab Drug: irinotecan hydrochloride Drug: vemurafenib Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Randomized Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

Resource links provided by NLM:


Further study details as provided by Southwest Oncology Group:

Primary Outcome Measures:
  • PFS (Arms I and II) [ Time Frame: From date of Step 2 Randomization to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years ]
    The primary analysis of PFS using the log rank test upon the observation of 63 progression events.

  • PFS (Crossover) [ Time Frame: From date of Step 3 Crossover Registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years ]

Secondary Outcome Measures:
  • Overall survival (Arms I and II) [ Time Frame: Up to 3 years ]
    Distributions of overall survival in Arms 1 and 2 will be estimated using the method of Kaplan-Meier.

  • Overall response rate [ Time Frame: Up to 3 years ]
    The overall response rate (confirmed and unconfirmed, complete and partial) in each treatment arm will be assessed in the subset of patients with measurable disease. Assuming 90% (n = 32 per arm) of patients will present with measurable disease, response rate can be estimated to within 18% (95% confidence interval).

  • Incidence of adverse events graded according to the National Cancer Institute CTCAE v4.0 [ Time Frame: Up to 3 years ]

Enrollment: 106
Study Start Date: November 2014
Estimated Study Completion Date: January 2020
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm I (cetuximab, irinotecan hydrochloride)
Patients receive cetuximab IV and irinotecan hydrochloride IV on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to Arm II.
Biological: cetuximab
Given IV
Other Names:
  • 11460
  • 205923-56-4
  • 3610
  • 714692
  • Anti-EGFR Monoclonal Antibody
  • Anti-Epidermal Growth Factor Receptor Monoclonal Antibody
  • C225
  • C225 monoclonal antibody
  • Chimeric Anti-EGFR Monoclonal Antibody
  • Chimeric MoAb C225
  • Chimeric Monoclonal Antibody C225
  • Erbitux
  • IMC-C225
  • Immunoglobulin G1
  • anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 gamma1-chain)
  • disulfide with human-mouse monoclonal C225 kappa-chain
  • dimer
  • MOAB C225
  • monoclonal antibody C225
Drug: irinotecan hydrochloride
Given IV
Other Names:
  • Campto
  • Camptosar
  • camptothecin-11
  • CPT-11
  • irinotecan
  • irinotecan HCl
  • U-101440E
Experimental: Arm II (cetuximab, irinotecan hydrochloride, vemurafenib)
Patients receive cetuximab and irinotecan hydrochloride as in Arm I and vemurafenib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Biological: cetuximab
Given IV
Other Names:
  • 11460
  • 205923-56-4
  • 3610
  • 714692
  • Anti-EGFR Monoclonal Antibody
  • Anti-Epidermal Growth Factor Receptor Monoclonal Antibody
  • C225
  • C225 monoclonal antibody
  • Chimeric Anti-EGFR Monoclonal Antibody
  • Chimeric MoAb C225
  • Chimeric Monoclonal Antibody C225
  • Erbitux
  • IMC-C225
  • Immunoglobulin G1
  • anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 gamma1-chain)
  • disulfide with human-mouse monoclonal C225 kappa-chain
  • dimer
  • MOAB C225
  • monoclonal antibody C225
Drug: irinotecan hydrochloride
Given IV
Other Names:
  • Campto
  • Camptosar
  • camptothecin-11
  • CPT-11
  • irinotecan
  • irinotecan HCl
  • U-101440E
Drug: vemurafenib
Given PO
Other Names:
  • BRAF(V600E) kinase inhibitor RO5185426
  • PLX4032
  • RG7204
  • RO5185426
  • Zelboraf

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • STEP I INITIAL REGISTRATION: BRAFV600E TESTING:
  • Patients must have histologically or cytologically documented adenocarcinoma of the colon or rectum that is either metastatic, or locally advanced and unresectable
  • Patients must have BRAFV600E mutant status documented by a Clinical Laboratory Improvements Amendments (CLIA) certified laboratory on a pathology report prior to Step 2 registration; use of an Food and Drug Administration (FDA)-approved test is preferred although other BRAF tests at a CLIA-certified laboratory may also be accepted; if a BRAFV600E mutation is known, then the patient must be registered to Step 2 Randomization immediately following Step 1 Initial Registration; if testing has not been performed locally, BRAFV600E testing must be completed by the central lab prior to Step 2 Randomization; if the specimen does not have a BRAFV600E mutation, the patient is ineligible for Step 2 Randomization
  • Brain metastases are allowed if they have been adequately treated with radiotherapy or surgery and stable for at least 90 days prior to Step 1 Initial Registration; eligible patients should be neurologically asymptomatic and without corticosteroid treatment for at least 7 days prior to Step 1 Initial Registration
  • Patients must have had one or two prior regimens of systemic chemotherapy for metastatic disease; prior treatment with irinotecan is allowed; a maintenance regimen of 5-fluorouracil or capecitabine, with or without bevacizumab, should not be counted as a separate line of treatment; prior treatment for metastatic disease is not required for patients who experienced disease recurrence during or within 6 months of completion of adjuvant chemotherapy
  • Patients must not have been treated with any of the following prior to Step 2 Randomization:

    • Cetuximab, panitumumab, or any other monoclonal antibody against EGFR or inhibitor of EGFR
    • BRAF inhibitor including, but not limited to, vemurafenib or dabrafenib; regorafenib is not considered a BRAF inhibitor for the purpose of determining trial eligibility
    • Mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitor including, but not limited to, trametinib or selumetinib
  • Previous chemotherapy, immunotherapy, or radiation therapy must have been completed at least 14 days prior to Step 1 Initial Registration and all toxicity must be resolved to Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) grade 1 (with the exception of CTCAE v4.0 grade 2 neuropathy) prior to Step 1 Initial Registration
  • Patients must not have a tumor with a mutation detected in codons 12 or 13 in KRAS; patients must not have a tumor with a known mutation detected in codons 61, 117, or 146 of KRAS or NRAS
  • SPECIMEN SUBMISSION CRITERIA:
  • Patients must have tumor (slides or block) available for submission for V600E BRAF testing
  • Patients must have additional tumor available and be willing to submit tissue and blood samples
  • SPECIMEN SUBMISSION CRITERIA REGULATORY CRITERIA:
  • Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines; for Step 1 Initial Registration of patients who have not yet submitted specimens for the central BRAFV600E testing, the appropriate consent form is the Step 1 Consent Form; for both Step 1 Initial Registration and Step 2 Randomization of patients whose BRAF mutation status is already known, the appropriate consent form is the Step 2 Consent Form
  • STEP 2 RANDOMIZATION:
  • Patients must have BRAFV600E mutation
  • Patients must have measurable or non-measurable metastatic disease; computed tomography (CT) scans or magnetic resonance imaging (MRIs) used to assess all disease must have been completed within 28 days prior to Step 2 Randomization; CT scans or MRIs must be assessed and documented on the Baseline Tumor Assessment Form (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
  • Patients must have a Zubrod performance status of 0-1
  • Absolute neutrophil count (ANC) >= 1,500/mcL
  • Platelets >= 100,00/mcL
  • Hemoglobin >= 9 g/dL
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal (IULN) or =< 5 x IULN if liver metastases are present
  • Total bilirubin =< 1.5 x IULN
  • Serum creatinine =< 1.5 x IULN within 14 days prior to Step 2 Randomization OR
  • Calculated creatinine clearance > 60 ml/min; the serum creatinine value used in the calculation must have been obtained within 14 days prior to Step 2 Randomization
  • Patients must have an electrocardiogram (ECG) within 14 days prior to Step 2 Randomization
  • Patients must have corrected QT (QTc) =< 500 msec
  • Patients must not have a known history of Gilbert's Syndrome or known homozygosity for the UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1)*28 allele
  • Patients must not have interstitial pneumonia or extensive symptomatic interstitial fibrosis of the lung
  • Patients must not have an uncontrolled intercurrent illness including, but not limited to, active bleeding diathesis, uncontrolled infection/disorders, nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy, or psychiatric illness/social situations which would limit compliance with study requirements
  • Patients must be able to swallow pill/tablet and have no refractory nausea, vomiting, malabsorption, external biliary shunt, or significant small bowel resection that would preclude adequate absorption
  • Patients must not be pregnant or nursing; women/men of reproductive potential must have agreed to use an effective contraceptive method while on study and for 30 days after study treatment; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures, he/she is responsible for beginning contraceptive measures
  • No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for three years
  • STEP 2 RANDOMIZATION REGULATORY CRITERIA:
  • Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines; for all patients, the appropriate consent form for this registration is the Step 2 Consent Form
  • As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
  • STEP 3 CROSSOVER REGISTRATION:
  • Patients must have documented disease progression while on Arm 1 of this protocol; the follow-up tumor assessment form documenting disease progression must be submitted to Southwestern Oncology Group (SWOG) prior to Step 3
  • Registration to Step 3 Crossover must be within 28 days of discontinuation of Arm 1 protocol treatment; patients going off treatment for any other reason are not eligible
  • ANC >= 1,500/mcL within 14 days prior to Step 3 registration
  • Platelets >= 100,00/mcL within 14 days prior to Step 3 registration
  • Hemoglobin >= 9 g/dL within 14 days prior to Step 3 registration
  • AST and ALT =< 2.5 x institutional upper limit of normal (IULN) or =< 5 x IULN if liver metastases are present within 14 days prior to Step 3 registration
  • Total bilirubin =< 1.5 x IULN within 14 days prior to Step 3 registration
  • Serum creatinine =< 1.5 x IULN within 14 days prior to Step 3 registration OR
  • Calculated creatinine clearance > 60 ml/min; the serum creatinine value used in the calculation must have been obtained within 14 days prior to Step 3 registration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02164916

  Show 763 Study Locations
Sponsors and Collaborators
Southwest Oncology Group
National Cancer Institute (NCI)
Genentech/Roche
Investigators
Principal Investigator: Edmund S Kopetz, M.D. M.D. Anderson
  More Information

Responsible Party: Southwest Oncology Group
ClinicalTrials.gov Identifier: NCT02164916     History of Changes
Other Study ID Numbers: S1406
U10CA180888 ( US NIH Grant/Contract Award Number )
S1406 ( Other Identifier: SWOG )
NCI-2014-00814 ( Other Identifier: NCI )
Study First Received: June 13, 2014
Last Updated: February 23, 2017

Keywords provided by Southwest Oncology Group:
BRAF Mutant
Metastatic

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Irinotecan
Camptothecin
Cetuximab
Antibodies
Immunoglobulins
Antibodies, Monoclonal
Immunoglobulin G
Mitogens
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs
Mitosis Modulators

ClinicalTrials.gov processed this record on June 23, 2017